Clinical Trial Update: A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL [Phase 1]

View source ↗

Summary

A dose-escalating Phase 1 pilot study of orelabrutinib in newly diagnosed primary central nervous system lymphoma is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Huashan Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING